Publikationen (133) Publikationen von JOSE CARLOS ARMARIO HITA

2024

  1. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)

    Journal of the European Academy of Dermatology and Venereology

  2. Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis (Dermatology and Therapy, (2024), 14, 1, (169-182), 10.1007/s13555-023-01058-z)

    Dermatology and Therapy

  3. Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

    JEADV Clinical Practice, Vol. 3, Núm. 1, pp. 191-200

  4. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

    Actas Dermo-Sifiliograficas

  5. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

    Dermatology and Therapy, Vol. 14, Núm. 1, pp. 169-182

  6. Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

    Dermatology and Therapy

  7. Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

    Actas Dermo-Sifiliograficas

  8. [Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

2023

  1. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

    International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706

  2. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

    Acta Dermato-Venereologica, Vol. 103

  3. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

  4. Pruritus and Pain Constitute the Main Negative Impact of Atopic Dermatitis From the Patient's Perspective: A Systematic Review

    Dermatitis

  5. Regular Exercise Improved Fatigue and Musculoskeletal Pain in Young Adult Psoriatic Patients without Psoriatic Arthritis

    Nutrients, Vol. 15, Núm. 21

  6. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results

    Journal of Investigational Allergology and Clinical Immunology

  7. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  8. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

  9. Updated Review on Treatment of Atopic Dermatitis

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167

2022

  1. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  2. Chronic hand eczema: clinical characterization, aetiology, concomitant foot eczema and polysensitization

    European journal of dermatology : EJD, Vol. 32, Núm. 1, pp. 99-106

  3. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

    Journal of Dermatological Treatment, Vol. 33, Núm. 1, pp. 266-277